Since EMT has been reported by several groups to enhance the resistance of cancer cells to anticancer drugs (reviewed in [9]), we evaluated the relative sensitivity of MCF-7-Snail and MCF-7-Control cells to a variety of cancer drugs previously and/or currently employed in breast cancer treatment (vincristine, doxorubicin [50], mitomycin C, methotrexate [51], gemcitabine, cisplatin [52] and 5-fluorouracil [53]). The gene discussed is SNAI1; the disease is breast carcinoma.